Xenomics, Inc. (Pink Sheets:XNOM, FWB:XE7) announces that it has granted
Warnex Medical Laboratories, a division of Warnex Inc., nonexclusive
rights in Canada to offer...
#13: XNOM News Xenomics Names Key Pharmaceutical Industry Executive John Brancaccio to Board of Directors and to Audit Committee; Seasoned Financial and Biotechnology Professional Brings Experience in Commercialization of New Technologies
NEW YORK--(BUSINESS WIRE)--Dec. 6, 2005--Xenomics, Inc. (OTCBB:XNOM)(FWB:XE7), a developer of next-generation medical DNA technologies, today announced its dual appointment of veteran biotechnology...
#12: XNOM News Xenomics to Present Breakthrough Medical DNA Technology at Rodman & Renshaw Techvest Healthcare Conference; Company to Outline Development of New Proprietary Transrenal-DNA Methods for Safe and Noninvasive Diagnosis of Diseases
NEW YORK--(BUSINESS WIRE)--Nov. 3, 2005--Xenomics, Inc. (OTCBB:XNOM)(FWB:XE7), a developer of next-generation medical DNA technologies, will present its breakthrough proprietary Transrenal-DNA...
#11: XNOM News Web Alert: Xenomics' Breakthrough DNA Technology to be Presented Today at Bio InvestorForum with Online Simulcast; CEO to Detail Revolutionary DNA Testing Technology Designed to Provide Noninvasive Diagnosis for Major Diseases
NEW YORK--(BUSINESS WIRE)--Oct. 20, 2005--Xenomics, Inc. (OTCBB: XNOM) (FSE: XE7), a developer of next-generation medical DNA technologies, announced that CEO Dr. Randy White will present its...
#10: XNOM News Xenomics' Breakthrough Transrenal-DNA Technology Platform to be Presented at Bio InvestorForum in San Francisco; Revolutionary DNA Testing Technology Could Provide Completely Noninvasive Detection Alternative for Major Diseases
NEW YORK--(BUSINESS WIRE)--Oct. 11, 2005--Xenomics, Inc. (OTCBB:XNOM) (FWB:XE7), a developer of next-generation medical DNA technologies, will present its breakthrough proprietary Transrenal-DNA...
#9: XNOM News Xenomics' Research Partner to Make Special Presentation of Clinical Data at Prestigious World Conference on Lung Health; Leading International Health Organization Recognizes Breakthrough Potential of Xenomics Proprietary Transrenal-DNA Platform
NEW YORK--(BUSINESS WIRE)--Sept. 22, 2005--Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, and its partner, Spaxen Italia, SRL, have been selected to present...
#8: XNOM News Xenomics' Novel Noninvasive Tr-DNA Technology Featured as Potential ``Amnio Alternative'' in Online News Article; Company CEO Dr. Randy White Discusses Breakthrough Medical Technology for Prenatal Diagnostic Testing in ``Herald News''
NEW YORK--(BUSINESS WIRE)--Sept. 8, 2005--Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, has been featured in the online news source the "Herald News," about...
#7: XNOM News Xenomics Featured in CNN Money Segment on its Development of Novel Noninvasive Prenatal Test to Detect Down Syndrome; CEO Dr. Randy White Discusses Development of Breakthrough Test Based on Proprietary Tr-DNA Technology in New Online Interview
NEW YORK--(BUSINESS WIRE)--Aug. 26, 2005--Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, announced today the online availability of an interview given by CEO...
#6: XNOM News Webalert: Xenomics CEO Randy White to Field Questions Today in Online Discussion with American Assoc. of Clinical Chemistry; CEO to Discuss Company's Commercialization of Proprietary Diagnostic Platform Technology for Biomedical Marketplace
NEW YORK--(BUSINESS WIRE)--Aug. 9, 2005--Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, has announced that CEO Dr. Randy White will be leading an online,...
#5: XNOM News Xenomics CEO Randy White to Present Tr-DNA in American Association of Clinical Chemistry Online Education Seminar; CEO to Field Questions on Company Plan to Commercialize Revolutionary Diagnostic Testing Technology During Interactive Program
NEW YORK--(BUSINESS WIRE)--Aug. 8, 2005--Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, has announced that CEO Dr. Randy White will be leading an online,...
#4: XNOM News Xenomics CEO Dr. Randy White to Present Company's Tr-DNA Technology Platform and Market Outlook at Frankfurt Stock Day; Participation at Respected European Financial Conference Expected to Enhance Strategic Relationships in International Communi
NEW YORK--(BUSINESS WIRE)--Aug. 5, 2005--Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, announced today that CEO Dr. Randy White will be presenting an...
#3: XNOM News Xenomics Granted European Patent for Breakthrough Tr-DNA Technology to Detect Fetal Genetic Abnormalities; New Patent Further Strengthens Xenomics' Strategy to Create and Distribute New Medical Diagnostic Products for International Market
NEW YORK--(BUSINESS WIRE)--July 27, 2005--Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, announced today it has been notified by the European Patent Office...
#2: XNOM News Xenomics to Present New Data Showing Improved Sensitivity for HIV Diagnostic Capabilities of Transrenal-DNA Technology; Company to Deliver Additional Data on Breakthrough Diagnostic Platform for HIV at AACC Meeting
Xenomics to Present New Data Showing Improved Sensitivity for HIV Diagnostic Capabilities of Transrenal-DNA Technology; Company to Deliver Additional Data on Breakthrough Diagnostic Platform for...
Xenomics Closes $2.77 Million Financing to Accelerate Development of Risk-Free Noninvasive Medical Testing Technology
Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA...
